-
IDEX reported past third quarter 2026 results with US$951.7 million in sales and US$1.95 in diluted EPS from continuing operations, both above the prior year.
-
Health & Science Technologies and other segments delivered strong orders and record adjusted earnings, which gives IDEX more room to reinvest in higher value applications.
-
Now the focus is on how IDEX's raised full year outlook may reshape its investment narrative and longer term earnings profile.
Scan how IDEX's earnings beat compares with other industrials showing strong momentum and balance sheets by reviewing the hand picked list of solid balance sheet and fundamentals (24 results) in the same space.
IDEX Investment Narrative Recap
To own IDEX, you essentially need to believe the push into higher value niches like health, science, data centers, semiconductors, space and defense can keep lifting the quality of earnings. The latest quarter, with US$951.7 million in sales and US$1.95 in diluted EPS from continuing operations, aligns with that story rather than changing it.
The near term swing factor still looks like execution in Health & Science Technologies and how efficiently new capacity is absorbed. The biggest risk remains a reversal in currently strong orders if policy shocks or geopolitics hit end markets, which could quickly pressure volumes, mix and margins despite the raised full year outlook.
The key announcement that ties directly into this is IDEX's Q3 2026 release. Management raised full year adjusted EPS guidance to a range centered around US$8.94 and highlighted record sales and adjusted diluted EPS. That move effectively indicates that IDEX sees enough demand and cost discipline to support stronger full year performance.
For catalysts, that higher bar raises the importance of converting the more than US$1b backlog and HST focused capital spending into steady organic sales and margin progression. On the risk side, if external research about muted organic growth and pressure on returns on capital persists despite this guidance lift, the gap between narrative and delivery could widen.
IDEX's analyst narrative points to about US$4.4b in revenue and US$781.0 million in earnings by 2029, based on forecasts that build in 6.7% yearly revenue growth and an earnings increase of roughly US$261.5 million from US$519.5 million today.
Uncover how IDEX's fair value indicates a 7% potential upside to its current price, which could narrow quickly if sentiment follows the upgraded outlook.
Exploring Other Perspectives
Two fair value estimates from the Simply Wall St Community cluster in a tight US$255.93 to US$281.68 band for IDEX, yet that narrow range still reflects very different expectations about how current earnings strength and the raised outlook hold up against policy risk and mixed research on organic growth. Opinions clearly diverge, so use these alongside other viewpoints before setting your own stance.
Explore another IDEX fair value estimate , including one that suggests as much as 18% upside from the current price.
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
-
A great starting point for your IDEX research is our analysis highlighting 3 key rewards that could impact your investment decision.
-
See our latest analysis for IDEX. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate IDEX's overall financial health at a glance.
Looking For More Ideas Beyond IDEX?
Once the IDEX story is clear in your mind, it often helps to compare it with a broader set of companies that share similar financial strengths or very different risk and reward profiles. The Simply Wall St Screener is a quick way to line up those contrasts and see which opportunities best fit your own style.
-
If you want potential mispricing backed by fundamentals, look through our 26 high quality undervalued stocks that combine quality with attractive pricing signals.
-
For investors who care most about resilience and capital preservation, focus on the 32 resilient stocks with low risk scores to see which businesses score strongest on financial stability.
-
When you are hunting for fresh opportunities beyond well known tickers, scan the 19 high quality undiscovered gems that pair strong fundamentals with lower market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IEX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
